“Private equity and start-up capitalization for emerging technologies are a crucial part of my retirement investment strategy. Most offerings are over-subscribed requiring immediate Subscription Agreement review, disclosure completion and capital calls. Once the offering is capitalized, the window closes. CTAS has performed the necessary due diligence and compliance and met every deadline for the past 10 years. They have the experience; they prioritize and they execute.”
Medical Tech Investor | Chief Innovation Executive & Physician